Eighty-four of 127 candidate statements reached at least 70% expert agreement to form the first international consensus on low-dose oral minoxidil for children under 12 — the lead item in this week's journal digest, which also covers subclinical inflammation during JAK-inhibitor treatment, genotype-driven growth deficits, total-body photography workflows, and radiofrequency microneedling for rosacea.

What does the minoxidil consensus recommend?

The modified Delphi study, published in JAMA Dermatology (September 30, 2026), involved 50 experts from 9 countries in its first two rounds; 49 completed the third. Of 127 initial items, 84 cleared the 70% agreement threshold.

The consensus supports use in children aged 4 to younger than 12 years for:

• follicular miniaturization
• hair cycle abnormalities
• hair shaft disorders
• adjunctive use in selected scarring alopecias

Weight-based and mg/kg dosing approaches both reached consensus, as did reassessment every 3 to 6 months. The authors frame the statement as a pediatric framework for patient selection, dosing, and monitoring — expert consensus, not prospective trial evidence, and it should be read within the context of off-label prescribing.

Does visible regrowth mean inflammation is gone?

A 60-week observational study in Dermatology and Therapy (October 2, 2026) followed 20 patients with alopecia areata treated with upadacitinib or baricitinib, pairing clinical assessment with videotrichoscopy and reflectance confocal microscopy (RCM). Mean Severity of Alopecia Tool (SALT) scores fell from 84.2 at baseline to 16.9 at week 60. Trichoscopy showed declining disease activity markers and progressive regrowth.

The catch sits below the surface. RCM identified persistent subclinical follicular and perifollicular inflammation in some patients despite visible improvement. Hair regrowth, in other words, may not fully capture underlying inflammatory activity.

Limits matter here: the cohort was small and nonrandomized, so the study cannot establish comparative drug efficacy, and whether residual RCM findings predict relapse remains unproven. The authors call for imaging as a complementary monitoring tool in further research.

Which genotypes drive growth deficits?

A registry-based cohort study in JAMA Dermatology tracked growth trajectories in 135 individuals with confirmed epidermal differentiation disorders, using pediatric measurements through age 18. Mean weight and height sat below the population median during the first 24 months, with meaningful differences by genotype.

Children with SPINK5 variants fared worst: at ages 25 to 48 months, mean weight and height were at the 17.7th and 6.8th percentiles, respectively, with persistent deficits. Early deficits associated with ABCA12 and KRT10 variants became less pronounced over time.

The practical takeaway is routine growth surveillance in children with inherited disorders of epidermal differentiation. Genotype may flag who needs closer monitoring and coordinated pediatric care, though the observational design cannot say which interventions improve growth.

Is total-body photography ready for routine practice?

A systematic review of 36 studies in the International Journal of Dermatology mapped how total-body photography (TBP) is deployed in skin cancer surveillance — imaging technologies, staff roles, workflows, and implementation factors. Despite 3-dimensional imaging and artificial intelligence advances, workflows were broadly consistent across settings and differed mainly in sequencing.

The evidence base is thin where it counts. Only 6 studies reported implementation aspects or related outcomes, and none used a formal implementation framework. For clinicians weighing TBP, the review argues for planning how imaging fits into existing care rather than fixating on equipment; which staffing and workflow models translate best into routine practice remains an open question.

Can radiofrequency microneedling treat rosacea?

A retrospective real-world cohort study in Clinical, Cosmetic and Investigational Dermatology evaluated radiofrequency microneedling in 50 adults with rosacea at a dermatology center in Seoul. Mean Rosacea Area and Severity Index scores decreased from 11.9 to 9.08, and mean erythema index fell from 2.48 to 1.58 — both statistically significant (P < .001).

Reported outcomes included lesion fading in 80% of patients and texture improvement in 72%. Three patients had mild adverse events that resolved within 96 hours.

Attribution is the problem. 68% of participants also received oral antibiotics, and concomitant treatment, retrospective photographic scoring, missing follow-up data, and the lack of a control group all prevent crediting the microneedling device alone. The findings support a potential adjunctive procedural role, but prospective controlled trials will need to clarify its incremental benefit over standard rosacea therapy.

Taken together, this week's papers push monitoring — imaging in alopecia areata, growth curves in genodermatoses, workflow design in TBP — toward the center of dermatologic practice, a shift likely to intensify as validation studies accumulate.